Here, we present a similar experimental approach to find therapeutic molecules active against mitochondrial diseases associated with dominant mutations in ANT1. Drugs were screened for their ability to suppress the defective respiratory growth of the haploid aac2M114P yeast mutant carrying the M114P substitution equivalent to L98P in adPEO patients. Here, SLC25A4 is linked to mitochondrial disease.